Janux Therapeutics
La Jolla, US · Founded 2017 · 122 employees on LinkedIn · 3 known investors
Janux Therapeutics develops precision-engineered bispecific immunotherapies, including tumor-activated T cell engagers (TRACTr), designed to modulate T cells to treat cancer and autoimmune diseases. Its lead clinical program targets prostate cancer.
Founders & leadership
DC
David Campbell, Ph.D.Executive
TR
Tighe ReardonExecutive
Board
JL
Jay Lichter, Ph.D.Board director
JS
Jake Simson, Ph.D.Board director
PT
Peter Thompson, M.D.Board director
SH
Stefan HellerBoard director
VL
Vickie L. CappsBoard director
SG
Sheila GujrathiBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$192.4M disclosed across 3 rounds · 2020–2021
▶$125MraisedApr 2021 · 22 investors · BiotechnologyRule 506(b)
▶$125MraisedApr 2021 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jay Lichter, Ph.D.Director
- Jake Simson, Ph.D.Director
- Stefan HellerDirector
- Peter Thompson, M.D.Director
- Vickie L. CappsDirector
- David Campbell, Ph.D.Executive Officer, Director
- Sheila GujrathiDirector
- Tighe ReardonExecutive Officer
- Offering amount
- $125M
- Amount sold
- $125M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$56MraisedMar 2021 · 7 investors · BiotechnologyRule 506(b)
▶$56MraisedMar 2021 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jay Lichter, Ph.D.Director
- Jake Simson, Ph.D.Director
- Tighe ReardonExecutive Officer
- Stefan HellerDirector
- Peter Thompson, M.D.Director
- David Campbell, Ph.D.Executive Officer, Director
- Offering amount
- $56M
- Amount sold
- $56M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$11.4MraisedJul 2020 · 3 investors · BiotechnologyRule 506(b)
▶$11.4MraisedJul 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jay Lichter, Ph.D.Director
- Stefan HellerDirector
- Tighe ReardonExecutive Officer
- David Campbell, Ph.D.Executive Officer, Director
- Offering amount
- $15.9M
- Amount sold
- $11.4M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Janux Therapeutics (JANX) Narrows Quarterly Losses, Is The Premium Valuation Too Rich? - Simply Wall St Newssimplywall.st · Aug 2026
Janux Therapeutics Q2 2026 results and cash position | JANX Quarterly Report (10-Q)stocktitan.net · Aug 2026Frequently asked questions
- What does Janux Therapeutics do?
- Janux Therapeutics develops precision-engineered bispecific immunotherapies, including tumor-activated T cell engagers (TRACTr), designed to modulate T cells to treat cancer and autoimmune diseases. Its lead clinical program targets prostate cancer.
- Who are Janux Therapeutics's investors?
- Janux Therapeutics's investors include Avalon BioVentures, OrbiMed, Samsara BioCapital.
- How much funding has Janux Therapeutics raised?
- Janux Therapeutics has disclosed $192.4M raised across 3 rounds.
- Where is Janux Therapeutics headquartered?
- Janux Therapeutics is headquartered in La Jolla, US.